Literature DB >> 3316049

B-cell lymphomas of high-grade malignancy frequently lack HLA-DR, -DP and -DQ antigens and associated invariant chain.

F Momburg1, B Herrmann, G Moldenhauer, P Möller.   

Abstract

The expression of HLA-DR, HLA-DP and HLA-DQ antigens was studied in an unselected series of 66 B-cell lymphomas by means of immunohistology using monoclonal antibodies against non-polymorphic determinants in a sensitive immunoperoxidase technique. In addition, the expression of the MHC class-II antigen-associated invariant chain (li) was examined. The tumors were classified according to the Kiel classification, 30 being of high-grade and 36 being of low-grade malignancy. Only 6 lymphomas of high-grade and 16 lymphomas of low-grade malignancy showed coordinate strong expression of all HLA class-II antigens and invariant chain as observed in the normal peripheral B cell. Six further tumors of high-grade and 8 tumors of low-grade malignancy contained tumor-cell subsets with reduced expression of one or several of the antigens. Eighteen lymphomas of high-grade and 12 lymphomas of low-grade malignancy contained varying tumor-cell subsets that were negative for HLA-DR, -DP, -DQ and li in a selective or combined manner. Three highly malignant tumors were devoid of all class-II antigens and li; 2 highly malignant tumors expressed invariant chain only. The presence of high-grade malignancy was significantly correlated with the occurrence of tumor cells lacking HLA-DR (p = 0.004), HLA-DP (p = 0.013), HLA-DQ (p = 0.007) or li (p = 0.024).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316049     DOI: 10.1002/ijc.2910400504

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.

Authors:  Sarah T Wilkinson; Kristie A Vanpatten; Diane R Fernandez; Patrick Brunhoeber; Karl E Garsha; Betty J Glinsmann-Gibson; Thomas M Grogan; Julie Teruya-Feldstein; Lisa M Rimsza
Journal:  Blood       Date:  2011-12-13       Impact factor: 22.113

Review 2.  Tumours of the thymus and their nomenclature.

Authors:  H F Otto
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

3.  Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials.

Authors:  Heinz-Wolfram Bernd; Marita Ziepert; Christoph Thorns; Wolfram Klapper; Hans-Heinrich Wacker; Michael Hummel; Harald Stein; Martin-Leo Hansmann; German Ott; Andreas Rosenwald; Hans-Konrad Müller-Hermelink; Thomas F E Barth; Peter Möller; Sergio B Cogliatti; Michael Pfreundschuh; Norbert Schmitz; Lorenz Trümper; Silvia Höller; Markus Löffler; Alfred C Feller
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

4.  Nonimmune human cells can express MHC class II antigens in the absence of invariant chain--an immunohistological study on normal and chronically inflamed small intestine.

Authors:  F Momburg; K Koretz; A Von Herbay; P Möller
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

5.  Evidence for an osteoblast-activating factor in a patient with peripheral T-cell lymphoma and osteosclerosis.

Authors:  M Hüfner; H Döhner; J Schmidt; P Möller; A D Ho; W Hunstein
Journal:  Klin Wochenschr       Date:  1989-04-03

6.  Microarray analysis of B-cell lymphoma cell lines with the t(14;18).

Authors:  Ryan S Robetorye; Sandra D Bohling; John W Morgan; G Chris Fillmore; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

7.  A retroviral mutagenesis screen identifies Cd74 as a common insertion site in murine B-lymphomas and reveals the existence of a novel IFNgamma-inducible Cd74 isoform.

Authors:  Magdalena Pyrz; Bruce Wang; Matthias Wabl; Finn Skou Pedersen
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

8.  Adhesion receptor profile of thymic B-cell lymphoma.

Authors:  A Eichelmann; K Koretz; G Mechtersheimer; P Möller
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

9.  Major histocompatibility complex class I and class II antigen expression in diffuse large cell and large cell immunoblastic lymphomas. Absence of a correlation between antigen expression and clinical outcome.

Authors:  L J Medeiros; A B Gelb; K Wolfson; R Doggett; B McGregor; R S Cox; S J Horning; R A Warnke
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

Review 10.  Antigen processing and immune regulation in the response to tumours.

Authors:  Emma Reeves; Edward James
Journal:  Immunology       Date:  2016-10-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.